FDA halts Juno CAR-T trial after three patient deaths

Juno Therapeutics ($JUNO) had hoped to have a very first approval for one of its candidates next year. But that looks unlikely to happen as the pivotal trial for this lead candidate has been put on hold by the FDA after three patient deaths.

The FDA initiated the clinical hold on the Phase II clinical trial of JCAR015, known as ROCKET, which is in adult relapsed or refractory B cell acute lymphoblastic leukemia. Contine reading →